These are some immunotherapy clinical trials at MD Anderson that were highlighted by Rene's oncologist. We'd like to bring them to your attention in case you are looking for immunotherapy trials.

Patients from outside the US can participate in these MD Anderson clinical trials. The cost of the drug is covered under the trial, but other expenses, such as scans, will have to be paid for out-of-pocket. Scans at MD Anderson are very expensive. We do not know what MD Anderson charges if you pay without insurance, but we can tell you that before insurance covers the scans, each scan costs several thousand US dollars. So do consider those costs before considering clinical trials in the US.

As of April 2017:

Immunotherapy trial: combination anti-PDL1 and anti-CTLA4 (Medimmune sponsored)

Status: 40 patients enrolled, and there’s a waitlist

Doctors:

Somiaiah (sarcoma) http://faculty.mdanderson.org/Neeta_Somaiah/

Conley (sarcoma) http://faculty.mdanderson.org/Anthony_Conley/

Subbiah (Phase I trial department at MD Anderson) http://faculty.mdanderson.org/Vivek_Subbiah/

 

Immunotherapy trial: NY-ESO-1 adoptive T cell therapy (Adaptimmune sponsored)

Cancer type: NY-ESO-1 expressing sarcomas (synovial sarcoma, myxoid liposarcoma) that are also HLA-A2

Clinical trial info: https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2015-0528.html

Doctor: Araujo http://faculty.mdanderson.org/Dejka_(Steinert)Araujo/

 

Immunotherapy trial: intratumoral injection of TLR agonist IMO-2125 (developed by Idera)

with anti-PD1 or anti-CTLA4

Cancer type: Metastatic Melanoma (but Sarcomas should be included as well)

Clinical trial info:

https://clinicaltrials.gov/ct2/show/NCT02644967

http://www.iderapharma.com/wp-content/uploads/2016/11/IMO-2125-An-Investigational-Intratumoral-Toll-Like-Receptor-9-Agonist-Modulates-the-Tumor-Microenvironment-to-Enhance-Anti-Tumor-Activity.pdf

Doctor: Diab http://faculty.mdanderson.org/Adi_Diab/Default.asp?SNID=0

 

Immunotherapy trial: systemic infusion of NKTR-214 (CD122 agonist that activates T cells +NK cells) (developed by Nektar) - altered IL2

Cancer type: Locally advanced or metastatic solid tumors

Clinical trial info: https://clinicaltrials.gov/ct2/show/NCT02869295

Doctors:

Diab http://faculty.mdanderson.org/Adi_Diab/Default.asp?SNID=0

Conley (sarcoma) http://faculty.mdanderson.org/Anthony_Conley/